Nutriband Inc. (NASDAQ: NTRB) has been granted a new U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology, a development that could play a pivotal role in enhancing drug safety amidst the ongoing opioid crisis. The AVERSA(TM) technology is specifically designed to prevent the misuse, abuse, and accidental exposure of transdermal drugs with high abuse potential, such as fentanyl, by incorporating features that deter abuse at the product level.
The opioid crisis remains a dire public health emergency in the U.S., with over 100,000 Americans dying annually from drug overdoses, many of which involve synthetic opioids like fentanyl. Nutriband's innovation represents a proactive approach to mitigating this crisis by addressing one of its root causes: the abuse of prescription drugs. By securing this patent, Nutriband expands its domestic intellectual property coverage, positioning its AVERSA(TM) technology as a scalable solution that could be applied across multiple therapeutic categories to prevent drug abuse.
This advancement underscores the pharmaceutical industry's ongoing efforts to balance the need for patient access to necessary medications with the imperative to prevent abuse. Nutriband's AVERSA(TM) technology exemplifies how innovative drug delivery systems can contribute to solving complex public health challenges. For more information on Nutriband's developments, visit https://ibn.fm/NTRB.
